Amyotrophic lateral sclerosis (ALS), commonly known as “Lou Gehrig’s disease,” is a rare neurodegenerative condition and one of the world’s five major incurable diseases. It is characterized by the gradual loss of neurons in the brain,...
Neuroresearchers at Macquarie University in Australia say they have developed a single-dose genetic medicine that has halted the progression of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in mice. The team, which believes its approach...
Even as Amylyx’s ALS drug gains steam in the U.S. after a long-awaited FDA approval, the company is struggling with regulatory hurdles overseas. This week, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against...
AcuraStem, a pioneering patient-based biotechnology company specializing in neurodegenerative disease treatments, has announced a groundbreaking partnership with Takeda to develop and commercialize targeted therapeutics for Amyotrophic Lateral Sclerosis (ALS) and...
